Laura Swartz

Recent Posts

Saleen Preps for 2015 Mustang; Reports Q2 Financials

Posted by Laura Swartz

November 17, 2014 at 10:56 AM

Saleen Automotive (SLNN-OTC) has reported its financial results for its second quarter and six months ended September 30, 2014. (Fiscal year end is March 31.)

The company experienced a slowdown in sales during the quarter due to a production switch by Ford from the 2014 Mustang to the 2015 Mustang. Ford discontinued supply of the 2014 Mustang chassis in May 2014, and did not start shipping on the 2015 until mid-November 2014. Saleen reports in its Form 10-Q filed with the SEC on Friday that many of its authorized resellers and dealers have preferred to place orders for the 2015 Saleen Mustang instead. To capitalize on anticipated 2015 demand, the company stated in its November 14th press release that it had "just recently received [the] initial shipment from Ford of the 2015 Mustangs and will begin production shortly."

Read More

Topics: Saleen

California Winemaker Truett-Hurst Reports 20% Increase in Sales for Q1 FY2015

Posted by Laura Swartz

November 11, 2014 at 10:46 AM

Nov. 10, 2014 /PRNewswire/ -- Truett-Hurst, Inc. (THST-NASDAQ) yesterday reported results for its first quarter fiscal 2015 ("FY15"), which ended September 30, 2014. Truett-Hurst, Inc. operates an innovative and fast growing super-premium and ultra-premium wine sales, marketing and production company based in the acclaimed Dry Creek and Russian River Valleys of Sonoma County, California.

Read More

Topics: Truett-Hurst

Biotech Company Amarantus Provides Business Update/Q3 2014 Financial Results

Posted by Laura Swartz

November 10, 2014 at 10:34 PM

On Monday, November 10, Amarantus Bioscience Holdings, Inc. started off the earnings week by reporting its third quarter 2014 (ended September 30) financial results. The company also recapped its milestones, updated investors on its product development status, and teased a potential new acquisition for the coming weeks. Lastly, the company also announced a strategic financing agreement with Dominion Capital that raises $3 million for Amarantus and extinguishes a prior promissory note held by Dominion. 

Read More

Topics: Amarantus

Boston Therapeutics Announces North American Branding of sugardown®

Posted by Laura Swartz

November 3, 2014 at 9:55 AM

Pharmaceutical company Boston Therapeutics, Inc. (BTHE-OTC) announced this morning that Benchworks SD, LLC has launched the branding of sugardown® in North America. Boston Therapeutics is a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, and sugardown® is the company's new natural dietary supplement product that helps people maintain healthy blood sugar levels. Boston Therapeutics states that sugardown® is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy.

Read More

Topics: BTHE

17 Awards in 2014 (so far!) for Winemaker Truett-Hurst

Posted by Laura Swartz

October 28, 2014 at 10:39 AM

Yesterday, Truett-Hurst Inc. (THST-NASDAQ) summed up nicely its numerous packaging awards and recognitions received in 2014 alone. The California winemaker is frequently recognized by the beverage industry for the quality of its wines, but also from the graphic design industry due to its packaging innovations and uniquely artistic style of branding its wines. The latter point hinges on the talents of the Company’s creative director, Kevin Shaw, who is founder of beverage design group Stranger & Stranger.

Download  Report For more on the Company, its wines, and its product design, please consult our Executive Informational Overview published on August 20, 2014.

Truett-Hurst’s 2014 Awards to Date in Packaging

Read More

Topics: Truett-Hurst

New Method to Improve Drug Discovery and Design Hinges on PCT

Posted by Laura Swartz

October 27, 2014 at 2:10 PM

Pressure BioSciences, Inc. (PBIO-OTC) reported this morning that it has received an important third-party validation of the protein analysis possibilities enabled by its proprietary pressure cycling technology (PCT). Earlier this month, at the 13th Human Proteome Organization World Congress in Madrid, Spain, renowned protein scientist Professor Ruedi Aebersold from ETH Zurich and the University of Zurich combined PCT with AB SCIEX’s SWATH mass spectrometry method, and was able to analyze thousands of proteins by mass spectrometry on small, needle biopsy samples. In presenting his process and findings, Dr. Aebersold noted that prior to the combination of the mass spectrometry method with Pressure BioSciences’ PCT platform, it had been nearly impossible to accomplish the quantification of thousands of proteins in needle biopsy samples.

Read More

Topics: Pressure BioSciences

Pressure BioSciences Partners With Powertech for Chinese Sales

Posted by Laura Swartz

October 20, 2014 at 10:45 AM

Laboratory instrumentation company Pressure BioSciences, Inc. (PBIO-OTC) announced this morning that it had entered into an exclusive, three-year distribution agreement with a Chinese distributor of analytical instruments and other equipment to China's biotech, pharma, agricultural, environmental, food safety, and commercial laboratory markets. Pressure BioSciences reports that the company, Powertech Technology Company Ltd., is a recognized distributor to the Chinese market, with a network of 18 distribution offices, a maintenance center, an applications laboratory, and multiple sub-dealers. The press release further stated that Powertech's current business partners aside from Pressure BioSciences include Dupont, GE Healthcare, Sartorius, Zeiss, and Agilent.

Read More

Topics: Pressure BioSciences

The Market May Be Down, But Amarantus is Up on Its News

Posted by Laura Swartz

October 16, 2014 at 11:20 AM

Biotechnology company Amarantus Bioscience Holdings, Inc. (AMBS-OTC) reported this morning that it had applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa. The company's stock appeared to be responding well to the news, and was up over 9% as of 11 am (ET).

Read More

Topics: Amarantus

Senior Analyst & CEO Jeff Kraws Discusses Ebola Therapies and Vaccines

Posted by Laura Swartz

October 15, 2014 at 1:15 PM

On Tuesday, October 14, Crystal Research Associates' senior pharmaceutical analyst and chief executive officer, Jeff Kraws, sat down with Andrew Schmertz, host of Arise TV's Xchange program, to discuss public and private efforts at curbing the Ebola outbreak.

Read More

Topics: Crystal Research Associates, Ebola

Study Data: Amarantus One Step Closer to a Q4 Launch of an Alzheimer's Blood Test

Posted by Laura Swartz

October 10, 2014 at 2:28 PM

Biotech company Amarantus Bioscience Holdings, Inc. (AMBS-OTC) has reported positive data from its LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD). LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls. As a result of these positive findings, Amarantus is expanding the study to assess LymPro's predictive value in diagnosing early-stage AD patients. Amarantus anticipates launching LymPro in the fourth quarter of 2014.

Read More

Topics: Amarantus

CardioComm Solutions (EKG) Becomes Approved Vendor to U.S. Government

Posted by Laura Swartz

October 9, 2014 at 12:26 PM

cardiocomm-logo-transAfter announcing last week that it would be implementing its SMART Monitoring-based HeartCheck™ ECG screening solution in select Rexall Pharmacies as part of the Canadian Stroke Prevention Intervention Network's ("C-SPIN") trial for atrial fibrillation screening and stroke prevention, CardioComm Solutions (EKG-TSX.V) today announced that it has become an approved vendor for the sale of HeartCheck products and ECG-based software solutions into numerous organizations within the umbrella of the U.S. Federal Government. As an active registrar in the U.S. Federal Government's System for Award Management (SAM), CardioComm Solutions is now eligible for contracts, assistance awards and to do business with the U.S. Federal Government and its agencies globally.

Read More

Topics: CardioComm Solutions

WABC-TV (New York) Spotlights MetaStat's Technology in 30-Minute Special

Posted by Laura Swartz

October 8, 2014 at 2:12 PM

On Sunday, October 5, 2014, an innovative molecular diagnostics technology from MetaStat, Inc. (MTST-OTC) was spotlighted in a WABC-TV news special.

Read More

Topics: MetaStat

Expanding Boston Therapeutics' Medical Advisory Board and Patentable Uses of BTI-320

Posted by Laura Swartz

October 8, 2014 at 1:45 PM

In addition to the leadership additions announced last week by Boston Therapeutics (BTHE-OTC), the company today announced that is has also appointed David S.H. Bell, MB, FACP, FACE, to its Medical Advisory Board. This increases the number of members of the Board to eight.

Read More

Topics: BTHE

Boston Therapeutics Ramps Up Sugardown®, Expands Board of Directors

Posted by Laura Swartz

October 3, 2014 at 12:51 PM

Pharmaceutical company Boston Therapeutics (BTHE-OTC) announced this week the launch of a new commercial phase for the company's sugardown® dietary supplement to help control glucose levels. Sugardown® is presently sold over-the-counter as a non-systemic, chewable dietary supplement taken prior to meals to support healthy blood sugar and help moderate post-meal blood glucose. The product works in the gastrointestinal tract to reduce the sharp spikes in blood sugar associated with eating carbohydrate foods. Sugardown® has previously been sold over the Internet in the U.S. and by distribution partners in China, Hong Kong, Macau, and South Korea.

Read More

Topics: BTHE

CardioComm Solutions' Technology Tapped for Stroke Prevention Trial

Posted by Laura Swartz

October 3, 2014 at 12:02 PM

CardioComm Solutions, Inc. (EKG-TSX.V) has announced that it would be implementing its SMART Monitoring-based HeartCheck™ ECG screening solution in select Rexall Pharmacies during October 2014. Rexall is a Canadian pharmacy chain that operates more than 450 locations across 180 communities in Canada. 

This news is part of the Canadian Stroke Prevention Intervention Network's ("C-SPIN") trial for atrial fibrillation screening and stroke prevention, for which in-pharmacy screening is taking place at 20 select Rexall locations across Ontario and Alberta. The trial uses CardioComm's technology to aid in its atrial fibrillation screening process. 

Read More

Topics: CardioComm Solutions

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic